Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
Authors
Keywords
-
Journal
JOURNAL OF CHEMOTHERAPY
Volume 26, Issue 6, Pages 333-338
Publisher
Informa UK Limited
Online
2013-11-05
DOI
10.1179/1973947813y.0000000145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New β-lactam-β-lactamase inhibitor combinations in clinical development
- (2013) David M. Shlaes Annals of the New York Academy of Sciences
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
- (2011) P. R. S. Lagacé-Wiens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current Challenges in Antimicrobial Chemotherapy
- (2010) Carine Bebrone et al. DRUGS
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Normalized Resistance Interpretation as a Tool for Establishing Epidemiological MIC Susceptibility Breakpoints
- (2010) Göran Kronvall JOURNAL OF CLINICAL MICROBIOLOGY
- In Vitro Activity of NXL104 in Combination with -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
- (2009) A. Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemases
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now